Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 5, 2006, Pages 577-585

  Hollander, Anna ^a   Foster, Graham R ^b   Weiland, Ola ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Health related quality of life; Hepatitis C virus; Interferon; Ribavirin; Sustained virological response

Indexed keywords

ALFANATIVE; ALPHA INTERFERON; HEMOGLOBIN; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; DISEASE TRANSMISSION; DRUG RESPONSE; EMOTION; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HEPATITIS C; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NONHUMAN; PATIENT COMPLIANCE; PATIENT SELECTION; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; ROLE PLAYING; SHORT FORM 36; SOCIAL STATUS; SWEDEN; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; QUALITY OF LIFE; RIBAVIRIN; SWEDEN;

EID: 33646476276     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520500325952     Document Type: Article

References (32)

1. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999;29:264-70.
2. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
3. Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004;39:74-80.
4. McHutchison JG, Ware JE, Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health-related quality of life and work productivity. J Hepatol 2001;34:140-7.
5. Ware JE, Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999;30:550-5.
6. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35:704-8.
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
8. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
9. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-7.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
11. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
13. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956-61.
14. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. June 10-12, 2002. Hepatology 2002;36 Suppl 1:S3-20.
15. Wejstal R, Alaeus A, Fischler B, Reichard O, Uhnoo I, Weiland O. Chronic hepatitis C: updated Swedish consensus. Scand J Infect Dis 2003;35:445-51.
16. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
17. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999;30:1299-301.
18. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000;32:654-9.
19. Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999;37:1567-9.
20. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34:2259-66.
21. Yun Z, Lara C, Johansson B, Lorenzana de Rivera I, Sonnerborg A. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996;49:155-60.
22. Sullivan M, Ware JE, Karlsson J, Sahlgrenska sjukhuset. Sektionen för vårdsforskning. SF-36 hälsoenkät: svensk manual och tolkningsguide (Swedish manual and interpretation guide). Göteborg: Sahlgrenska sjukhuset Sektionen för vårdforskning; 1994.
23. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
24. McHorney CA, Ware JE, Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
25. McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
26. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15:141-55.
27. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
28. Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999;6:237-42.
29. Hollander A, Glaumann H, Weiland O. Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre. Scand J Gastroenterol 2004;39:164-7.
30. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
31. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologie response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
32. Shiffman ML, Morgan TR, Ghany MG, Wright EC, Group atH-CT. The impact of peginterferon (pegifn) and ribavirin dosing on sustained virologie response in patients with chronic hepatitis C virus undergoing retreatment in the halt-C trial. Hepatology 2004;40 Suppl 1:314A.